Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib:efficacy and safety  

作　　者：Xiaojun Huang Qian Jiang Jianda Hu Jianyong Li Jie Jin Fanyi Meng Zhixiang Shen Ting Liu Depei Wu Jianmin Wang Jianxiang Wang 

机构地区：[1]Peking University People's Hospital,Beijing 100044,China [10]The Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Science & Peking Union Medical College,Tianjin 300020,China [2]Fujian Medical University Union Hospital,Fuzhou 350004,China [3]The First Affiliated Hospital with Nanjing Medical University,Nanjing 210029,China [4]The First Affiliated Hospital of The College of Medicine,Zhejiang University,Hangzhou 310058,China [5]Guangzhou Nanfang Hospital,Guangzhou 510515,China [6]Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [7]West China Hospital,Sichuan University,Chengdu 610041,China [8]The First Affiliated Hospital of Soochow University,Suzhou 215006,China [9]Changhai Hospital of Shanghai,Shanghai 200433,China

出　　处：《Frontiers of Medicine》2019年第3期344-353,共10页医学前沿（英文版）

摘　　要：Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML).In 2007,a pivotal phase-2 study of dasatinib as second-line treatment was initiated in 140 Chinese CML patients.This report from the 4-year follow-up revealed that 73% of 59 patients in chronic phase (CML-CP) and 32% of 25 patients in accelerated phase (CML-AP) remained under treatment.The initial dosage of dasatinib for CML-CP and CML-AP patients were 100 mg once daily and 70 mg twice daily (total=140 mg/ day),respectively.The cumulative major cytogenetic response (MCyR) rate among patients with CML-CP was 66.1%(versus 50.8% at 18 months),and the median time to MCyR was 12.7 weeks.All CML-CP patients who achieved MCyR after a 4-year follow-up also achieved a complete cytogenetic response.The cumulative complete hematological response (CHR) rate among patients with CML-AP was 64%(16/25),with three CML-AP patients achieving CHR between 18 months and 4 years of follow-up;the median time to CHR was 16.4 weeks.The adverse event (AE) profile of dasatinib at 4 years was similar to that at 6 and 18 months.The most frequently reported AEs (any grade) included pleural effusion,headache,and myelosuppression.These long-term follow-up data continue to support dasatinib as a second-line treatment for Chinese patients with CML.

关 键 词：chronic MYELOID LEUKEMIA (CML) DASATINIB TYROSINE kinase inhibitor long-term FOLLOW-UP 

分 类 号：R[医药卫生]